Inhibikase Therapeutics (IKT)

• Market cap: $109M
• 1 day: -0.68%
• 5 days: -5.81%
• 1 month: -12.05%
• 3 months: -8.75%
• 6 months: -30.14%
• Year to date: -55.62%
• 1 year: -44.06%
• 5 years: -97.54%
• 10 years: -97.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Employees: 16